Savior Lifetec

Savior Lifetec EV/FCF

The EV/FCF (Enterprise Value to Free Cash Flow) of Savior Lifetec (4167.TWO) as of Oct 27, 2026 is -35.91. In the previous year, EV/FCF (Enterprise Value to Free Cash Flow) was 16.44 — a change of -318.36% (lower).

EV/FCF

-35.91

YoY

-318.36%

Last updated:

EV/FCF (Enterprise Value to Free Cash Flow) of Savior Lifetec is 2025 -35.91 . EV/FCF (Enterprise Value to Free Cash Flow) of Savior Lifetec was 2024 16.44 . It decreases by -318.36% lower compared to the previous year.

The Savior Lifetec EV/FCF history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/FCF
Date
EV/FCF
Jan 1, 2018
-16.79 TWD
Jan 1, 2019
-157.94 TWD
Jan 1, 2020
-48.34 TWD
Jan 1, 2021
-24.03 TWD
Jan 1, 2022
9.23 TWD
Jan 1, 2023
13.06 TWD
Jan 1, 2024
16.44 TWD
Jan 1, 2025
-35.91 TWD
The Savior Lifetec EV/FCF history
YEAREV/FCFYoY
-35.91-318.36%
16.44+25.95%
13.06+41.52%
9.23-138.39%
-24.03-50.29%
-48.34-69.40%
-157.94+840.47%
-16.79-133.12%
50.71-221.69%
-41.67+320.21%
-9.92-30.83%
-14.34—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Savior Lifetec Stock analysis

What does Savior Lifetec do? Savior Lifetec Corp develops, produces, and sells active pharmaceutical ingredients and finished dosage formulations, including Meropenem, Imipenem/Cilastatin, and Ertapenem, which are used as broad-spectrum antibiotics. The company provides APIs intermediates and bio-pharmaceutical technology services, distributing its products to Europe, the Americas, Asia, and other global markets. Its primary revenue streams come from the sale of pharmaceutical products and technology services to international markets. The company's product portfolio focuses on antibiotics such as Meropenem and Ertapenem, which are sold as finished dosage formulations. APIs intermediates are supplied to clients in the pharmaceutical industry, while bio-pharmaceutical technology services support clients in drug development and manufacturing. These offerings target global pharmaceutical companies seeking reliable supply chains and technical expertise. Savior Lifetec Corp's customers include pharmaceutical firms in Europe, the Americas, Asia, and other regions that require active pharmaceutical ingredients and specialized technology services. The company generates revenue through direct sales of its antibiotic formulations and API intermediates, as well as through contractual agreements for bio-pharmaceutical technology services. Savior Lifetec is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Savior Lifetec stock

EV/FCF (Enterprise Value to Free Cash Flow) of Savior Lifetec is -35.91 in 2025.

EV/FCF (Enterprise Value to Free Cash Flow) of Savior Lifetec changed from 16.44 to -35.91, representing a -318.36% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/FCF (Enterprise Value to Free Cash Flow) Savior Lifetec since 2006 – with annual values, charts, and detailed analysis.

The EV/FCF ratio measures the enterprise value relative to free cash flow. It captures the true cash-generating ability of a business.

To evaluate EV/FCF (Enterprise Value to Free Cash Flow)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/FCF (Enterprise Value to Free Cash Flow).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/FCF (Enterprise Value to Free Cash Flow)'s Savior Lifetec with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Savior Lifetec

All Key Metrics — Savior Lifetec